Core Informatics Names Josh Geballe as CEO
News Oct 03, 2013
Core Informatics announced that it has hired IBM executive Josh Geballe to serve as Chief Executive Officer.
"I am thrilled to be joining the Core team at such an exciting time," said Geballe. "Core is uniquely positioned to help its clients drive scientific advancements with its innovative suite of Software as a Service (SaaS) and upcoming Platform as a Service (PaaS) capabilities. I look forward to working with the visionary team at Core to help companies maximize the value of their scientific data and increase their productivity to support rapid innovation and growth."
Geballe has served most recently as an IBM Vice President leading a large division of the company's Global Technology Services business providing managed, cloud and consulting services to enterprise clients across the United States. Previously, he was Chief Financial Officer for two multi-billion dollar IBM business units, including two years based in London where he was the Vice President and CFO for IBM's European Technology Services business that provides IT outsourcing and technology project-based services.
"The addition of Josh to our senior management team represents a significant milestone in the development of Core Informatics," said Anthony Uzzo, President and Co-Founder. "The unique value proposition of our Core LIMS, ELN and SDMS products has gained strong momentum and recognition in each of the industries we serve as enterprises shift to platform technologies. Josh's role in fostering the growth of the company increases our capacity to drive product innovation and value to our clients."
Geballe holds an MBA from the Yale School of Management, and a BA from Yale University.
HIV-1 replicates in ninja-like ways. The virus slips through the membrane of vital white blood cells. Inside, HIV-1 copies its genes and scavenges parts to build a protective bubble for its copies. Now, supercomputers have helped model a key building block in the HIV-1 protective capsid, which could lead to strategies for potential therapeutic intervention in HIV-1 replication.READ MORE